Erratum to: Inflammatory breast cancer with excellent response to pembrolizumab-chemotherapy combination: A case report

Authors

Zeni Kharel, Rochester Regional HealthFollow
Omar P. Nemer, Department of Radiology, University of Rochester Medical Center, Rochester, NY, USA.
Wang Xi, Department of Pathology, University of Rochester Medical Center, Rochester, NY, USA.
Bimala Upadhayaya, Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Carla I. Falkson, Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Ruth M. O'Regan, Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Ajay Dhakal, Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.

Department

Internal Medicine

Document Type

Erratum

Publication Title

Breast Disease

Abstract

Erratum for:

Inflammatory breast cancer with excellent response to pembrolizumab-chemotherapy combination: A case report. Kharel Z, Nemer OP, Xi W, Upadhayaya B, Falkson CI, O'Regan RM, Dhakal A. Breast Dis. 2022;41(1):255-260. doi: 10.3233/BD-210041. PMID: 35599460

First Page

363

DOI

10.3233/BD-229001

Volume

41

Issue

1

Publication Date

8-31-2022

PubMed ID

36057835

Recommended Citation

Kharel, Z., Nemer, O. P., Xi, W., Upadhayaya, B., Falkson, C. I., O'Regan, R. M., & Dhakal, A. (2022). Erratum to: Inflammatory breast cancer with excellent response to pembrolizumab-chemotherapy combination: A case report. Breast Disease, 41 (1), 363. https://doi.org/10.3233/BD-229001